Completed

LV strainEcho Study - Characterization of LV Strain Patterns in Patients With Mildly Elevated PCWP and Pulmonary Hypertension

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

sildenafil

Drug
Who is being recruted

Cardiovascular Diseases+7

+ Heart Diseases

+ Hypertension, Pulmonary

From 18 to 80 Years
+13 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Diagnostic Study

Phase 4
Interventional
Study Start: February 2013
See protocol details

Summary

Principal SponsorUniversity of Arizona
Last updated: November 4, 2015
Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 2013

Actual date on which the first participant was enrolled.

The purpose of this study is to determine if patients with pulmonary hypertension and mildly elevated heart pressure known as PCWP will exhibit different patterns on echocardiography and that these patterns will predict treatment response to sildenafil, a drug given for this condition.

Principal SponsorUniversity of Arizona
Last updated: November 4, 2015
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

9 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Diagnostic Study

Diagnostic studies focus on improving how we detect or confirm a disease. They test new tools or techniques that could provide faster or more accurate diagnoses.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 80 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Cardiovascular DiseasesHeart DiseasesHypertension, PulmonaryLung DiseasesRespiratory Tract DiseasesVascular DiseasesVentricular DysfunctionHypertensionVentricular Dysfunction, LeftFamilial Primary Pulmonary Hypertension

Criteria

6 inclusion criteria required to participate
6 minute walk distance > 150 meters and < 450 meters

Age > 18 and < 80

No evidence of active ischemic heart disease

Patients with New York Heart Association/World Health Organization(NYHA/WHO)functional class II-III

Show More Criteria

7 exclusion criteria prevent from participating
Contraindications to right heart catheterization

Contraindications to submaximal exercise testing

Left ventricular ejection fraction < 50%

Moderate-severe aortic and mitral valve abnormality

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Subjects will have 2D-Echocardiogram measuring left ventricular strain and strain rate using speckle tracking techniques, have 6 minute walk test, World Health Organization functional class (I-IV)assignment, and BNP lab result at baseline and at 3 months. Subjects will be started on sildenafil at 20 mg by mouth three times per day at the baseline visit. Each individual will serve as his/her own control.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

University of Arizona Medical Center

Tucson, United StatesOpen University of Arizona Medical Center in Google Maps
CompletedOne Study Center